|
|
|
|
|
|
by pak
3623 days ago
|
|
|
Hmm, well as a counterpoint to your point about the FDA, fidaxomicin was approved in 2011 for general use against C. difficile colitis, because it showed certain outcomes that compared favorably against the current standard of care (oral vancomycin) [1]. The reason it isn't used more often is probably because it is one of the most expensive antibiotics available. Antibiotics aren't typically approved only as "last resort"; it remains at the discretion of the physician to jump straight to the big guns before drug susceptibility test results are available (which is part of the problem). [1] https://en.wikipedia.org/wiki/Fidaxomicin |
|
|